Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evixapodlin - Gilead Sciences

Next Previous
Drug Profile

Evixapodlin - Gilead Sciences

Alternative Names: GS-4224; Oral PD-L1 small molecule inhibitor - Gilead Sciences; OX-4224

Latest Information Update: 18 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gilead Sciences
  • Developer Gilead Sciences; OmRx Oncology
  • Class Antineoplastics; Antivirals; Small molecules
  • Mechanism of Action Programmed cell death-1 ligand-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I/II Solid tumours
  • Phase I Hepatitis B

Most Recent Events

  • 18 May 2025 Phase-II clinical trials in Non-small cell lung cancer (Metastatic disease, Second-line therapy or greater, Monotherapy) in India (PO)
  • 15 Nov 2024 Phase-I clinical trials in Hepatitis B in Australia (PO) (ACTRN12618001843246p)
  • 15 Nov 2024 Efficacy and adverse event data from phase Ib trial in Hepatitis B presented at the 75th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2024 )

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top